A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

General Key Inclusion Criteria * Written informed consent before the first study-related activity * Be male or female ≥ 18 years of age * If female, have a negative serum pregnancy test at Screening and further negative urine tests immediately before each dose of study medication if the participant is a female of childbearing potential. General Key Exclusion Criteria * Be pregnant or breastfeeding * Have a history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening * Have uncontrolled blood pressure, defined as systolic ≥180 mmHg and/or diastolic ≥100 mmHg while a participant is at rest. * Have had Yttrium-Aluminum Garnet laser capsulotomy in the study eye within 90 days of Screening * Have had Pan-retinal Photocoagulation or focal thermal laser photocoagulation in the study eye * Have tractional retinal detachment in the study eye * Have uncontrolled glaucoma (defined as IOP ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye BRVO-specific Inclusion Criteria Participants must: * Be diagnosed with BRVO in the study eye * Have a ETDRS BCVA letter score between ≤ 70 and ≥ 35 (20/40 to 20/200 Snellen equivalent) in the study eye * Have a CST of ≥ 325 μm in the study eye on SDOCT as determined by the IRC at Screening * Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO BRVO-specific Exclusion Criteria Participants must not: * Have macula…